QTRX

Class Action Firm Recognition: Monteverde & Associates PC, a leading class action firm based in New York, has been recognized as a Top 50 Firm for recovering millions for shareholders and is currently investigating several proposed mergers involving companies like Paragon 28, Beacon Roofing Supply, Quanterix Corporation, and Playa Hotels & Resorts.

Shareholder Actions and Deadlines: Shareholders of the mentioned companies are encouraged to act promptly regarding upcoming votes and tender offers, with specific deadlines set for April 14 and April 25, 2025, while also being offered free consultations to address any concerns.

New DBS Extraction Kit: Quanterix Corporation has introduced a dried blood spot (DBS) extraction kit at the International Conference on Alzheimer's and Parkinson's Diseases, allowing for cost-effective and less invasive measurement of low-concentration biomarkers in neurodegenerative disease research.

Impact on Research Accessibility: The new kit aims to simplify sample collection, enhancing participation in Alzheimer's research and clinical trials, particularly among under-represented populations, while Quanterix's Simoa technology is featured in over 80 presentations at the conference.

Analyst Rating Changes: Several Wall Street analysts have adjusted their price targets and ratings for various companies, including Verizon (up to $45), Plains All American Pipeline (up to $23), and Goldman Sachs (up to $625), while downgrading Akoya Biosciences (down to $1.8) and others.

Stock Performance: The current stock prices reflect these changes, with Verizon at $43.56, Plains All American Pipeline at $20.17, and Akoya Biosciences at $1.67, indicating mixed market reactions to the analysts' updates.

Tikvah Management's Position: Tikvah Management LLC, a significant shareholder of Quanterix Corp., plans to vote against the proposed merger with Akoya Biosciences, citing concerns over undervaluation and potential cash flow reduction.

Investor Sentiment: Tikvah aligns with other investors who oppose the merger, arguing that Quanterix's business is superior to that of Akoya.

Board Changes at Sera Prognostics: Jeff Elliott will join the Board of Directors on March 20, 2025, while Ryan Trimble plans to retire on June 30, 2025, after 14 years with the company. Marcus Wilson will also not seek re-election at the upcoming Annual Meeting.

Company's Mission and Product: Sera Prognostics focuses on improving maternal and neonatal health through innovative pregnancy biomarker information, particularly with their PreTRM® test that predicts preterm birth risk, aiming for commercialization following successful study results.

Price Target Adjustment: Canaccord has lowered Quanterix's price target from $20 to $15 while maintaining a Buy rating, citing the company's undervaluation despite concerns over its merger with Akoya Biosciences potentially affecting share prices.

Financial Performance Overview: Quanterix reported strong revenue growth in Q4 with an EPS of (30c) compared to (23c) last year, and projects FY25 revenue between $140M-$146M, below the consensus estimate of $154.7M.

Financial Performance: Quanterix Corp reported Q4 2024 revenue of $35.2 million, an 11% increase year-over-year, with notable growth in Accelerator lab revenue (22%) and a non-GAAP gross margin improvement to 57.7%. However, instrument revenue declined by 7% year-over-year.

Future Outlook: The company anticipates modest revenue growth of 2% to 6% for 2025, facing challenges such as market volatility and delays in large pharma contracts, while also pursuing an acquisition of Akoya Biosciences to enhance profitability and scale.

Financial Performance: Quanterix Corporation reported an 11% revenue growth in Q4 2024, marking its seventh consecutive quarter of double-digit growth, despite a net loss of $11.6 million. The company also announced plans to acquire Akoya Biosciences to enhance its biomarker detection capabilities.

Future Outlook: For 2025, Quanterix anticipates revenue growth between 2% and 6%, with expected cash usage of approximately $55 million to $65 million, which includes upfront payments for the recent acquisition of EMISSION.

Kent Lake's Opposition: Kent Lake PR LLC, holding 7.47% of Quanterix Corporation's stock, opposes the proposed merger with Akoya Biosciences, arguing it significantly undervalues Quanterix and encourages shareholders to vote against the transaction to protect their investments.

Concerns Raised: Kent Lake has raised multiple concerns regarding the merger, including disproportionate value distribution favoring Akoya, potential conflicts of interest within the Board, and the lack of transparency regarding risks associated with NIH funding and Akoya's financial health.

Earnings Reports Overview: Several companies, including Belite Bio, Harrow, and Open Lending Corporation, are set to report their earnings for the quarter ending December 31, 2024, with varying forecasts and past performance comparisons.

Performance Trends: Most companies reported losses in the previous year, with some showing significant decreases in earnings per share, while a few, like Belite Bio and DiaMedica Therapeutics, demonstrated improvements compared to last year's results.

Q4 Financial Performance: Quanterix reported a Q4 GAAP EPS of -$0.30, missing expectations by $0.05, but achieved revenue of $35.2 million, which is an 11.6% year-over-year increase and exceeded estimates by $0.27 million.

Full Year Highlights: For the full year 2024, Quanterix generated $137.4 million in revenue (up 12% from the previous year), with a net loss of $38.5 million, which is a reduction of $10.2 million compared to the prior year.

Financial Performance: Akoya Biosciences reported a revenue decline of 15.5% for the full year 2024, totaling $81.7 million, while achieving improved gross margins and reduced operating expenses compared to the previous year.

Business Developments: The company announced its pending acquisition by Quanterix Corporation, which aims to enhance capabilities in ultra-sensitive detection of biomarkers, alongside launching new products and expanding partnerships in the spatial biology market.

Conference Call Announcement: Quanterix Corporation will host a conference call on March 17, 2025, at 4:30 p.m. E.T. to discuss its fourth quarter and full year 2024 financial results, with a press release issued prior to the call.

Company Overview: Quanterix specializes in ultrasensitive biomarker detection technology, supporting research in various medical fields, and has been a trusted partner in scientific discovery for nearly two decades.

Conference Call Announcement: Quanterix Corporation will host a conference call on March 17, 2025, at 4:30 p.m. E.T. to discuss its fourth quarter and full year 2024 financial results, with a press release issued prior to the call.

Company Overview: Quanterix specializes in ultrasensitive biomarker detection technology, supporting research in various medical fields and has been a trusted partner in the scientific community for nearly two decades.

Transaction Concerns: Kent Lake PR LLC opposes Quanterix's proposed merger with Akoya Biosciences, arguing that it significantly undervalues Quanterix and introduces unnecessary risks, particularly diverting focus from its Alzheimer's diagnostics program.

Call to Action for Shareholders: Kent Lake urges Quanterix shareholders to vote against the merger, citing governance issues and a lack of trust in the current Board, while advocating for independent candidates to be elected at the upcoming annual meeting.

Kent Lake's Activist Stance: Kent Lake PR LLC, a significant shareholder in Quanterix Corporation, has nominated three independent candidates for the Board of Directors due to concerns over a proposed merger with Akoya Biosciences, which they believe would harm shareholder interests.

Nominees' Expertise: The nominated candidates—Alexander G. Dickinson, Bruce Felt, and Hakan Sakul—bring extensive experience in life sciences, finance, and clinical diagnostics, aiming to enhance accountability and focus on Quanterix's growth opportunities in research and Alzheimer's testing.

Quanterix Acquisition of Akoya: Quanterix Corporation is pursuing the acquisition of Akoya Biosciences to enhance its capabilities in biomarker detection, potentially unlocking a $15 billion market across various medical fields and generating significant cost synergies.

Kent Lake Nominations: Kent Lake PR LLC has nominated three candidates for Quanterix's Board of Directors, which the company views as an attempt to undermine the strategic rationale behind the Akoya acquisition; the Board will review these nominations ahead of the 2025 Annual Meeting.

Investigation of Companies: Bragar Eagel & Squire, P.C. is investigating potential claims against Quanterix Corporation, e.l.f. Beauty, Inc., and Silvaco Group, Inc. for possible violations of federal securities laws and unlawful business practices.

Stock Price Impact: Each company experienced significant stock price declines following disclosures of financial inaccuracies or negative reports, with Quanterix's stock dropping 18.3%, e.l.f. Beauty's falling 15%, and Silvaco's decreasing by 32.64%.

Opposition to Merger: Kent Lake PR LLC, holding 5.9% of Quanterix Corporation's stock, opposes the proposed merger with Akoya Biosciences, arguing it significantly undervalues Quanterix and poses financial risks to its shareholders.

Concerns Raised: The letter from Kent Lake highlights issues such as a substantial valuation disparity, potential financial instability post-merger, and distractions from critical growth opportunities in Alzheimer's diagnostics.

Investigation of Quanterix Corporation: Rosen Law Firm is investigating potential securities claims against Quanterix Corporation due to allegations of misleading business information, which led to a significant drop in the company's stock price following the announcement of non-reliance on previously issued financial statements.

Class Action Participation: Investors who purchased Quanterix securities may be eligible for compensation through a class action lawsuit without upfront costs, and they can join by contacting the Rosen Law Firm for more information.